CR8095A - Anticuerpos humanizados que reconocen el cuerpo beta amiloideo - Google Patents

Anticuerpos humanizados que reconocen el cuerpo beta amiloideo

Info

Publication number
CR8095A
CR8095A CR8095A CR8095A CR8095A CR 8095 A CR8095 A CR 8095A CR 8095 A CR8095 A CR 8095A CR 8095 A CR8095 A CR 8095A CR 8095 A CR8095 A CR 8095A
Authority
CR
Costa Rica
Prior art keywords
humanized antibodies
amiloideo
beta
antibodies recognizing
recognizing
Prior art date
Application number
CR8095A
Other languages
English (en)
Inventor
Guriq Basi
Jose W Saldanha
Frederique Bard
Original Assignee
Wyeth Corp
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp, Elan Pharma Int Ltd filed Critical Wyeth Corp
Publication of CR8095A publication Critical patent/CR8095A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invencion se relaciona con agentes mejorados y metodos para el tratamiento de enfermedades asociadas con depositos de amiloide de AB en el cerebro del paciente. Los agentes preferentes incluyen anticuerpos, por ejemplo anticuerpos humanizados.
CR8095A 2003-05-30 2005-11-16 Anticuerpos humanizados que reconocen el cuerpo beta amiloideo CR8095A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47465403P 2003-05-30 2003-05-30

Publications (1)

Publication Number Publication Date
CR8095A true CR8095A (es) 2007-11-23

Family

ID=33511618

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8095A CR8095A (es) 2003-05-30 2005-11-16 Anticuerpos humanizados que reconocen el cuerpo beta amiloideo

Country Status (31)

Country Link
US (1) US7871615B2 (es)
EP (1) EP1636268B8 (es)
JP (1) JP4908203B2 (es)
KR (2) KR101152583B1 (es)
CN (1) CN1798766B (es)
AR (1) AR044580A1 (es)
AT (1) ATE545656T1 (es)
AU (1) AU2004245989B2 (es)
BR (1) BRPI0410860A (es)
CA (1) CA2525975C (es)
CO (1) CO5660296A2 (es)
CR (1) CR8095A (es)
DK (1) DK1636268T3 (es)
EA (1) EA012407B1 (es)
EC (1) ECSP056263A (es)
ES (1) ES2382547T3 (es)
HK (1) HK1088617A1 (es)
IL (1) IL171877A (es)
MX (1) MXPA05012718A (es)
MY (1) MY176959A (es)
NO (1) NO20055415L (es)
NZ (1) NZ544324A (es)
PE (1) PE20050627A1 (es)
PL (1) PL1636268T3 (es)
PT (1) PT1636268E (es)
SI (1) SI1636268T1 (es)
TW (2) TWI306458B (es)
UA (1) UA90846C2 (es)
UY (1) UY28337A1 (es)
WO (1) WO2004108895A2 (es)
ZA (1) ZA200509585B (es)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1594969B1 (en) * 2003-02-01 2015-05-20 Janssen Sciences Ireland UC Active immunization to generate antibodies to soluble a-beta
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
AU2005294131A1 (en) * 2004-10-05 2006-04-20 Wyeth Methods and compositions for improving recombinant protein production
WO2007050359A2 (en) * 2005-10-21 2007-05-03 Merck & Co., Inc. Anti-addl monoclonal antibody and use thereof
JP4979388B2 (ja) 2004-10-29 2012-07-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 炎症性疾患治療剤
CA2590337C (en) * 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
WO2006066049A2 (en) * 2004-12-15 2006-06-22 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
EP1838349A1 (en) * 2004-12-15 2007-10-03 Neuralab, Ltd. Amyloid beta antibodies for use in improving cognition
WO2006081171A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
MX2007009091A (es) * 2005-01-28 2008-01-11 Wyeth Corp Formulaciones de polipeptido liquidas estabilizadas.
ES2318918B1 (es) * 2005-04-01 2010-02-16 Biotherapix Molecular Medicines, S.L.U. Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones.
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
US7825223B2 (en) 2005-06-17 2010-11-02 Janssen Alzheimer Immunotherapy Methods of purifying anti A β antibodies
KR101439828B1 (ko) 2005-11-30 2014-09-17 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
EP2361638B1 (en) * 2005-12-12 2014-01-15 AC Immune S.A. A beta 1-42 specific monoclonal antibodies with therapeutic properties
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
TWI551607B (zh) * 2006-07-14 2016-10-01 Ａｃ免疫公司 人類化抗體
EP2076287A2 (en) * 2006-10-12 2009-07-08 Wyeth Methods and compositions with reduced opalescence
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP3239175A1 (en) 2007-01-05 2017-11-01 University of Zurich Method of providing disease-specific binding molecules and targets
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
ES2533484T3 (es) 2007-04-18 2015-04-10 Probiodrug Ag Derivados de tiourea como inhibidores de la glutaminil ciclasa
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
CN104761641A (zh) * 2007-06-12 2015-07-08 Ac免疫有限公司 β淀粉样蛋白的人源化抗体
HUE027507T2 (en) 2007-06-25 2016-10-28 Esbatech Alcon Biomed Res Unit Procedures for Modifying Antibodies and Modified Antibodies with Improved Functional Properties
SI2182983T1 (sl) * 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
EP2020602A1 (en) * 2007-08-02 2009-02-04 Araclon Biotech High sensitivty immunoassays and kits for the determination of peptides and proteins of biological interest
CN101883791B (zh) * 2007-10-05 2015-11-25 基因技术公司 人源化抗体
AU2008311366B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
PT2238166E (pt) 2007-10-05 2014-02-11 Genentech Inc Utilização do anticorpo anti-amilóide beta em doenças oculares
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2261254A3 (en) 2007-12-21 2011-04-13 Amgen, Inc Anti-amyloid antibodies and uses thereof
JO2913B1 (en) * 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
AU2009269700B2 (en) * 2008-07-09 2015-07-16 University Of Zurich Method of promoting neurogenesis
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2010056893A1 (en) * 2008-11-13 2010-05-20 Imclone Llc Humanization and affinity-optimization of antibodies
NZ593964A (en) 2008-12-19 2012-12-21 Univ Zuerich Human anti-alpha-synuclein autoantibodies
US8614297B2 (en) 2008-12-22 2013-12-24 Hoffmann-La Roche Inc. Anti-idiotype antibody against an antibody against the amyloid β peptide
CN101463082B (zh) * 2009-01-16 2011-12-28 清华大学 与A-beta寡聚体特异性结合的基因工程单克隆抗体
CN101463083B (zh) * 2009-01-16 2011-12-28 清华大学 与A-beta寡聚体特异性结合的基因工程单克隆抗体
CN101463085B (zh) * 2009-01-16 2011-09-14 清华大学 与A-beta寡聚体特异性结合的基因工程单克隆抗体
EA022007B1 (ru) 2009-09-11 2015-10-30 Пробиодруг Аг Гетероциклические производные в качестве ингибиторов глутаминилциклазы
JO3437B1 (ar) * 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
SG183369A1 (en) 2010-03-03 2012-09-27 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
KR101790806B1 (ko) 2010-03-10 2017-11-20 프로비오드룩 아게 글루타미닐 사이클라제(ｑｃ, ｅｃ 2.3.2.5)의 헤테로사이클릭 억제제
WO2011130377A2 (en) * 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
CN103298833B (zh) * 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
US9580493B2 (en) 2011-06-23 2017-02-28 Biogen International Neuroscience Gmbh Anti-α synuclein binding molecules
JP2012050437A (ja) * 2011-09-12 2012-03-15 Janssen Alzheimer Immunotherapy ベータアミロイドペプチドを認識するヒト化抗体
UA119235C2 (uk) 2013-05-20 2019-05-27 Дженентек, Інк. Антитіло анти-рецептор трансферину і способи його застосування
US9587032B2 (en) * 2013-06-12 2017-03-07 The Board Of Trustees Of The Leland Stanford Junior University IgE antibodies for the inhibition of tumor metastasis
SI3041513T1 (sl) 2013-09-08 2020-11-30 Kodiak Sciences Inc. Zwitterionski polimerni konjugati faktorja VIII
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3207128B1 (en) 2014-10-17 2022-07-27 Kodiak Sciences Inc. Butyrylcholinesterase zwitterionic polymer conjugates
EP3221362B1 (en) 2014-11-19 2019-07-24 F.Hoffmann-La Roche Ag Anti-transferrin receptor antibodies and methods of use
WO2016081640A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
JP2018502840A (ja) 2014-12-10 2018-02-01 ジェネンテック， インコーポレイテッド 血液脳関門受容体抗体及び使用方法
WO2017079831A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
WO2017079833A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
EP3374383A4 (en) * 2015-11-09 2019-05-15 The University Of British Columbia BETA-AMYLOID EPITOPES AND ASSOCIATED ANTIBODIES
JP2016047839A (ja) * 2015-11-24 2016-04-07 ヤンセン・サイエンシズ・アイルランド・ユーシー アミロイド原性疾患の処置
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
AU2018321335A1 (en) 2017-08-22 2020-02-27 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
CN111094340B (zh) * 2018-07-17 2022-11-22 江苏恒瑞医药股份有限公司 抗Abeta抗体、其抗原结合片段及应用
AU2019354965A1 (en) 2018-10-04 2021-05-06 University Of Rochester Improvement of glymphatic delivery by manipulating plasma osmolarity
AR117453A1 (es) 2018-12-20 2021-08-04 Genentech Inc Fc de anticuerpos modificados y métodos para utilizarlas
CN111518206B (zh) * 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
JP2023535024A (ja) 2020-07-23 2023-08-15 オター プロシーナ リミテッド 抗ａベータ抗体
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies

Family Cites Families (280)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4713366A (en) 1985-12-04 1987-12-15 The Ohio State University Research Foundation Antigenic modification of polypeptides
US5096706A (en) 1986-03-25 1992-03-17 National Research Development Corporation Antigen-based treatment for adiposity
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5278049A (en) 1986-06-03 1994-01-11 Incyte Pharmaceuticals, Inc. Recombinant molecule encoding human protease nexin
US5231170A (en) 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US5187153A (en) 1986-11-17 1993-02-16 Scios Nova Inc. Methods of treatment using Alzheimer's amyloid polypeptide derivatives
US5220013A (en) 1986-11-17 1993-06-15 Scios Nova Inc. DNA sequence useful for the detection of Alzheimer's disease
US4879213A (en) 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US4912206A (en) 1987-02-26 1990-03-27 The United States Of America As Represented By The Department Of Health And Human Services CDNA clone encoding brain amyloid of alzheimer's disease
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5583112A (en) 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5245015A (en) 1991-04-26 1993-09-14 Tanox Biosystems, Inc. Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5571500A (en) 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5869054A (en) 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US5641474A (en) 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
ATE258065T1 (de) 1987-06-24 2004-02-15 Brigham & Womens Hospital Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen
US5849298A (en) 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5645820A (en) 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5571499A (en) 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5231000A (en) 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
CA1339014C (en) 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
JP2518911B2 (ja) 1987-10-23 1996-07-31 森永乳業株式会社 ｃ―ｆｍｓ癌原遺伝子の過剰発現によって特徴づけられた癌の処置用組成物および方法
US5089603A (en) 1989-06-21 1992-02-18 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted iga
AU3056289A (en) 1988-01-13 1989-08-11 Mclean Hospital Corporation, The Genetic constructs containing the alzheimer brain amyloid gene
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5576184A (en) 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5227159A (en) 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
US5262332A (en) 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
AU5439790A (en) 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10
WO1990012870A1 (en) 1989-04-14 1990-11-01 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
JPH0744798B2 (ja) * 1989-07-10 1995-05-15 シーメンス アクチエンゲゼルシヤフト 大形回転電機のための導体巻線装置
DK0506785T3 (da) 1989-12-20 2000-07-24 Autoimmune Inc Forbedret behandling af autoimmune sygdomme ved aerosol-administration af autoantigener
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69127470T2 (de) 1990-03-02 1998-02-19 Autoimmune Inc Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
CA2079880A1 (en) 1990-04-24 1991-10-25 William E. Van Nostrand Purification, detection and methods of use of protease nexin-2
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
JP2980677B2 (ja) 1990-04-27 1999-11-22 マクマイケル，ジョン 不正常なアミロイドβタンパク質と関連する中枢神経系疾患状態の治療のための方法および組成物
AU646877B2 (en) 1990-06-15 1994-03-10 Scios Nova Inc. Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
US5780587A (en) 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5702906A (en) 1990-09-25 1997-12-30 Genentech, Inc. Antibodies to neurotrophic factor-4 (NT-4)
AU8768191A (en) 1990-09-28 1992-04-28 Upjohn Company, The Transgenic animals with alzheimer's amyloid precursor gene
AU9023791A (en) 1990-10-15 1992-05-20 Brigham And Women's Hospital Treatment of autoimmune diseases by oral administration of autoantigens
EP0971033B1 (en) 1991-01-21 2009-10-28 Elan Pharmaceuticals, Inc. Test and model for Alzheimer's disease
US5192753A (en) 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5672805A (en) 1991-07-18 1997-09-30 The Regents Of The University Of California Transgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor protein
US5434050A (en) 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
DE69233109T2 (de) 1992-01-07 2004-05-19 Elan Pharmaceuticals, Inc., San Francisco Transgene tiermodelle fur alzheimer-krankheit
US5679348A (en) 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
ATE245446T1 (de) 1992-02-11 2003-08-15 Jackson H M Found Military Med Dualer träger für immunogene konstrukte
CA2117492C (en) 1992-02-28 2009-04-07 Howard L. Weiner Bystander suppression of autoimmune diseases
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5441870A (en) 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5851787A (en) 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
GB9209118D0 (en) 1992-04-28 1992-06-10 Sb 120 Amsterdam Bv Vaccine compositions
ATE188508T1 (de) 1992-06-18 2000-01-15 Harvard College Impfstoffe gegen diphtherietoxin
DE69327599T2 (de) 1992-06-25 2000-08-10 Smithkline Beecham Biolog Adjuvantien enthaltende Impfstoffzusammensetzung
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
WO1994001772A1 (en) 1992-07-13 1994-01-20 The Children's Medical Center Corporation SCREEN FOR ALZHEIMER'S DISEASE THERAPEUTICS BASED ON β-AMYLOID PRODUCTION
DK0652962T3 (da) 1992-07-31 1999-08-23 Medeva Holdings Bv Ekspression af rekombinante fusionsproteiner i attenuerede bakterier
EP0667786B1 (en) 1992-08-27 2004-01-21 Deakin Research Limited Retro-, inverso-, and retro-inverso synthetic peptide analogues
US5958883A (en) 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
WO1994009364A1 (en) 1992-10-13 1994-04-28 Duke University Method of inhibiting binding of amyloid precursor protein to beta-amyloid protein
DK1298436T3 (da) 1992-10-26 2010-10-25 Elan Pharm Inc Fremgangsmåde til identificering af inhibitorforbindelser for frisætning af beta-amyloidpeptid (BAP)
US5605811A (en) 1992-10-26 1997-02-25 Athena Neurosciences, Inc. Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
EP0683234B2 (en) 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
CA2158455C (en) 1993-03-17 2003-05-27 Nicholas P. Restifo Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide and their uses in vaccines and disease treatments
ATE204762T1 (de) 1993-03-23 2001-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
IT1270939B (it) 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
WO1994028412A1 (en) 1993-05-28 1994-12-08 The Miriam Hospital Composition and method for in vivo imaging of amyloid deposits
US5464823A (en) 1993-07-20 1995-11-07 The Regents Of The University Of California Mammalian antibiotic peptides
ATE215124T1 (de) 1993-07-30 2002-04-15 Medeva Holdings Bv Rekombinante tetc-fusionsprotein enthaltene impfstoffzusammensetzungen
EP0664814A1 (en) 1993-08-18 1995-08-02 MorphoSys AG Lipopolysaccharide-binding and neutralizing peptides
AU707083B2 (en) 1993-08-26 1999-07-01 Bavarian Nordic Inc. Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes
EP0714308A4 (en) 1993-08-26 1998-07-29 Univ California METHOD, COMPOSITIONS AND DEVICES FOR THE DELIVERY OF NAKED POLYNUCLEOTIDES THAT ENCODE BIOLOGICALLY ACTIVE PEPTIDES
WO1995006407A1 (en) 1993-08-30 1995-03-09 The Regents Of The University Of California Novel component of amyloid in alzheimer's disease and methods for use of same
EP0730609B1 (en) * 1993-09-07 2005-01-05 Smithkline Beecham Corporation Recombinant il4 antibodies useful in treatment of il4 mediated disorders
US5652334A (en) 1993-09-08 1997-07-29 City Of Hope Method for design of substances that enhance memory and improve the quality of life
US5385887A (en) 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
ATE415173T1 (de) 1993-09-14 2008-12-15 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
US5470951A (en) 1993-09-29 1995-11-28 City Of Hope Peptides for antagonizing the effects of amyloid βprotein
US5858981A (en) 1993-09-30 1999-01-12 University Of Pennsylvania Method of inhibiting phagocytosis
JPH09506170A (ja) 1993-10-20 1997-06-17 デューク・ユニヴァーシティ β‐アミロイドペプチドに物質を結合する方法
DK0724431T3 (da) 1993-10-22 2003-01-06 Genentech Inc Fremgangsmåder og sammensætninger til mikroindkapsling af adjuvanser
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5434170A (en) 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
CA2182311A1 (en) 1994-01-27 1995-08-03 Karen Hsiao Transgenic non-human mammals with progressive neurologic disease
US5935927A (en) 1994-02-03 1999-08-10 The Picower Institute For Medical Research Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts
AUPM411994A0 (en) 1994-02-25 1994-03-24 Deakin Research Limited Epitopes
US5795954A (en) 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
ATE202940T1 (de) 1994-05-25 2001-07-15 John Mcmichael Mittel und methoden zur behandlung von plaque- krankheiten
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US6417178B1 (en) 1994-07-19 2002-07-09 University Of Pittsburgh Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
US6114133A (en) 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5589154A (en) 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
DE69620877T2 (de) 1995-02-06 2002-12-12 Genetics Inst Arzneimittelformulierungen für il-12
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US5624937A (en) 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
US6303567B1 (en) 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
DE69621607T2 (de) 1995-03-14 2003-01-02 Praecis Pharm Inc VERBINDUNGEN MIT AGGREGATIONS-MODULIERENDEN WIRKUNG AUF DAS AMYLOiD PROTEIN
US5854215A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
US5817626A (en) 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
ATE274064T1 (de) 1995-05-23 2004-09-15 Morphosys Ag Multimere proteine
AU6113896A (en) 1995-06-05 1996-12-24 Brigham And Women's Hospital Use of oral tolerance to suppress both th1 and th2 immune re sponses and to suppress antibody production
DK0750907T3 (da) 1995-06-30 2002-07-08 American Cyanamid Co Stabile vaccinepræparater til parenteral administrering, en fremgangsmåde til deres anvendelse og en fremgangsmåde til deres fremstilling
CA2226255A1 (en) 1995-07-07 1997-01-30 Darwin Molecular Corporation Chromosome 1 gene and gene products related to alzheimer's disease
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DE69621940T2 (de) 1995-08-18 2003-01-16 Morphosys Ag Protein-/(poly)peptidbibliotheken
AU6898996A (en) 1995-08-21 1997-03-12 Cytrx Corporation Compositions and methods for growth promotion
ES2218598T3 (es) 1995-09-14 2004-11-16 The Regents Of The University Of California Anticuerpo especifico del prpsc natural.
US5731284A (en) 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US5985242A (en) 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US5750361A (en) 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
ES2203722T3 (es) 1995-11-10 2004-04-16 Elan Corporation, Plc Peptidos que faccilitan el transporte a traves de tejidos y metodos de identificarlos y usarlos.
WO1997021728A1 (en) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
WO1997032017A1 (en) 1996-02-26 1997-09-04 Morphosys Gesellschaft Für Proteinoptimierung Mbh Novel method for the identification of nucleic acid sequences encoding two or more interacting (poly)peptides
US6150091A (en) 1996-03-06 2000-11-21 Baylor College Of Medicine Direct molecular diagnosis of Friedreich ataxia
US6284533B1 (en) 1996-05-01 2001-09-04 Avant Immunotherapeutics, Inc. Plasmid-based vaccine for treating atherosclerosis
CA2267620A1 (en) 1996-07-16 1998-01-22 Andreas Pluckthun Immunoglobulin superfamily domains and fragments with increased solubility
CA2183901A1 (en) 1996-08-22 1998-02-23 Johanna E. Bergmann Targets for therapy and diagnosis of alzheimer's disease and down syndrome in humans
ES2245003T3 (es) 1996-08-27 2005-12-16 Praecis Pharmaceuticals Incorporated Moduladores de la agregacion de peptidos beta-amiloides que comprenden d-aminoacidos.
US6057367A (en) 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
US6797495B2 (en) 1996-11-05 2004-09-28 The Regents Of The University Of California Somatic cells with ablated PrP gene and methods of use
US6022859A (en) 1996-11-15 2000-02-08 Wisconsin Alumni Research Foundation Inhibitors of β-amyloid toxicity
AU5508798A (en) 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
US6962984B2 (en) 1996-12-05 2005-11-08 Nihon University IgA nephropathy-related DNA
US20030068316A1 (en) 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5798102A (en) 1997-03-04 1998-08-25 Milkhaus Laboratory, Inc. Treatment of cardiomyopathy
DK0994728T3 (da) 1997-04-09 2008-12-01 Intellect Neurosciences Inc Rekombinante antistoffer, som er specifikke for beta-amyloide ender, DNA, der koder derfor, samt fremgangsmåder til anvendelse heraf
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US20020086847A1 (en) 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
US6787319B2 (en) 1997-04-16 2004-09-07 American Home Products Corp. β-amyloid peptide-binding proteins and polynucleotides encoding the same
WO1998052581A1 (en) 1997-05-20 1998-11-26 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
ATE230277T1 (de) 1997-06-13 2003-01-15 Genentech Inc Stabilisierte antikörperformulierung
WO1999000150A2 (en) 1997-06-27 1999-01-07 Regents Of The University Of California Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
IT1293511B1 (it) 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
WO1999006545A2 (en) 1997-08-01 1999-02-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation
WO1999006587A2 (en) 1997-08-01 1999-02-11 Morphosys Ag Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
ATE435661T1 (de) 1997-08-29 2009-07-15 Antigenics Inc Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel
US6175057B1 (en) 1997-10-08 2001-01-16 The Regents Of The University Of California Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy
DE69828574T2 (de) * 1997-11-14 2005-10-06 Sankyo Co., Ltd. Transgenes Tier als Modell für Allergie und seine Verwendung
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
BR9815345A (pt) 1997-12-03 2000-11-21 Fujisawa Pharmaceutical Co Composição mole de droga peletizada, inalador utilizando a mesma e método para sua fabricação
EP1033998B1 (en) 1997-12-03 2005-10-19 Neuralab, Ltd. Suppressing beta-amyloid-related changes in alzheimer's disease
FR2777015B3 (fr) 1998-02-23 2000-09-15 Financ De Biotechnologie Procede et moyens pour l'obtention de modeles cellulaires et animaux de maladies neurodegeneratives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US20050059802A1 (en) 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US20050059591A1 (en) 1998-04-07 2005-03-17 Neuralab Limited Prevention and treatment of amyloidogenic disease
CA2327505A1 (en) 1998-04-28 1999-11-04 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
NO314086B1 (no) 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
EP1080110A2 (en) 1998-05-19 2001-03-07 Yeda Research And Development Co. Ltd. Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
CA2325600A1 (en) 1998-05-21 1999-11-25 The University Of Tennessee Research Corporation Methods for amyloid removal using anti-amyloid antibodies
US6727349B1 (en) 1998-07-23 2004-04-27 Millennium Pharmaceuticals, Inc. Recombinant anti-CCR2 antibodies and methods of use therefor
EE200100203A (et) 1998-10-05 2002-10-15 M & E Biotech A/S Meetod immuunvastuse indutseerimiseks polüpeptiidse antigeeni vastu ja rakuga seotud polüpeptiidse antigeeni mahasurumiseks loomorganismil, selle meetodi kasutamine eesnäärme- ja rinnavähi raviks ning immunogeenne kompositsioon
CA2354862A1 (en) 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
WO2000043049A1 (en) 1999-01-19 2000-07-27 Pharmacia & Upjohn Company Gamma-irradiation sterilized polyethylene packaging
JP2002535289A (ja) 1999-01-22 2002-10-22 ドウアリング，マシユー・ジヨン 神経疾患のワクチン媒介治療
WO2000068263A2 (en) 1999-05-05 2000-11-16 Neurochem, Inc. Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
AR024558A1 (es) 1999-06-01 2002-10-16 Neuralab Ltd Composiciones del peptido a-beta y procesos para producir las mismas
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
CA2376693C (en) 1999-06-16 2013-09-10 Boston Biomedical Research Institute Immunological control of .beta.-amyloid levels in vivo
PL360914A1 (en) 1999-07-15 2004-09-20 Genetics Institute Inc. Formulations for il-11
ES2235926T3 (es) 1999-08-04 2005-07-16 The University Of Southern California Ensamblaje globular de proteina beta amiloide y sus usos.
JP2003509020A (ja) 1999-09-03 2003-03-11 ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
WO2001039796A2 (en) 1999-11-29 2001-06-07 Neurochem Inc. Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
EP1237930B1 (en) 1999-12-08 2006-11-08 Intellect Neurosciences, Inc. Chimeric amyloid beta peptides
US6399314B1 (en) 1999-12-29 2002-06-04 American Cyanamid Company Methods of detection of amyloidogenic proteins
CA2400838C (en) 2000-02-21 2013-04-23 Pharmexa A/S Novel method for down-regulation of amyloid
JP5025871B2 (ja) 2000-02-21 2012-09-12 エイチ．リュンドベック エイ／エス アミロイドの新規なダウン−レギュレート方法
EP1257584B2 (en) 2000-02-24 2013-03-06 Washington University St. Louis Humanized antibodies that sequester amyloid beta peptide
US6992984B1 (en) * 2000-03-07 2006-01-31 Lucent Technologies Inc. Credit-based adaptive flow control for multi-stage multi-dimensional switching architecture
US7485616B2 (en) 2000-04-05 2009-02-03 University Of Tennessee Research Foundation Methods of investigating, diagnosing, and treating amyloidosis
DE60108111T2 (de) 2000-05-22 2005-12-08 New York University Synthetische immunogene jedoch nicht amyloidogene peptide, die homolog zu amyloid beta sind und deren verwendung zur induktion einer immunantwort gegen amyloid beta und amyloidaggregate
EP1309341A2 (en) 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
EP1172378A1 (en) 2000-07-12 2002-01-16 Richard Dr. Dodel Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
US20020009445A1 (en) 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
US20030092145A1 (en) 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
US7067133B2 (en) 2000-09-06 2006-06-27 Aventis Pharma S.A. Methods and compositions for diseases associated with amyloidosis
IT1319277B1 (it) 2000-10-24 2003-09-26 Chiesi Farma Spa Proteine di fusione utili per il trattamento di immunizzazione dellamalattia di alzheimer.
IL139308A0 (en) 2000-10-26 2001-11-25 Marikovsky Moshe Peptides from amyloid precursor protein which inhibit tumor growth and metastasis
WO2002042462A2 (en) 2000-11-27 2002-05-30 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US6900036B2 (en) 2000-12-27 2005-05-31 University Of Texas Health Science Center Houston Prion isomers, methods of making, methods of using, and compositions and products comprising prion isomers
WO2002059621A2 (en) 2001-01-24 2002-08-01 Bayer Corporation Regulation of transthyretin to treat obesity
EP1251138B1 (en) 2001-04-19 2006-07-26 Hermann Dr. Schätzl Prion protein dimers useful for vaccination
ATE409047T1 (de) 2001-04-30 2008-10-15 Lilly Co Eli Humanisierte antikörper
ES2318006T3 (es) * 2001-04-30 2009-05-01 Eli Lilly And Company Anticuerpos humanizados que reconocen el peptido beta-amiloide.
US6906169B2 (en) 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US20020197258A1 (en) 2001-06-22 2002-12-26 Ghanbari Hossein A. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
JP4317010B2 (ja) 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
US20030135035A1 (en) 2001-08-09 2003-07-17 Mark Shannon Human ZZAP1 protein
US20060073149A1 (en) 2001-08-17 2006-04-06 Bales Kelly R Rapid improvement of cognition in condition related to abeta
JP2005503789A (ja) 2001-08-17 2005-02-10 イーライ・リリー・アンド・カンパニー 抗Ａβ抗体
WO2003016467A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass
US20030082191A1 (en) 2001-08-29 2003-05-01 Poduslo Joseph F. Treatment for central nervous system disorders
US7781413B2 (en) 2001-10-31 2010-08-24 Board Of Regents, The University Of Texas System SEMA3B inhibits tumor growth and induces apoptosis in cancer cells
DK1441589T3 (da) 2001-11-08 2012-08-06 Abbott Biotherapeutics Corp Stabil, flydende, farmaceutisk sammensætning af IgG-antistoffer
CA2466841A1 (en) 2001-11-21 2003-06-05 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid .beta., prion protein, amylin, .alpha.-synuclein, or polyglutamine repeats for induction of an immune response thereto
AU2002366355A1 (en) 2001-12-17 2003-06-30 New York State Office Of Mental Health SEQUESTRATION OF ABeta IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
KR20040094705A (ko) 2002-02-21 2004-11-10 듀크 유니버시티 자가면역질환에 대한 시약 및 치료 방법
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
EP1911765A3 (en) 2002-07-24 2008-04-23 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with Beta-Amyloid formation and/or aggregation
AU2003279728B2 (en) 2002-10-01 2007-09-27 Northwestern University Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
FR2846667B1 (fr) 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
US6787129B1 (en) 2003-01-13 2004-09-07 Zenitech Llc Castor polyester as gloss agents in anionic systems
EP1594969B1 (en) 2003-02-01 2015-05-20 Janssen Sciences Ireland UC Active immunization to generate antibodies to soluble a-beta
DE602004027348D1 (de) 2003-02-10 2010-07-08 Applied Molecular Evolution Abeta-bindende moleküle
ZA200507757B (en) 2003-04-04 2007-01-31 Genentech Inc High concentration antibody and protein formulations
EP1480041A1 (en) 2003-05-22 2004-11-24 Innogenetics N.V. Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
WO2005014041A2 (en) 2003-07-24 2005-02-17 Novartis Ag Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases
US20060233788A1 (en) 2003-09-05 2006-10-19 Heiman Mark L Anti-ghrelin antibodies
WO2005058940A2 (en) 2003-12-17 2005-06-30 Wyeth Immunogenic peptide carrier conjugates and methods of producing same
EA009559B1 (ru) 2003-12-17 2008-02-28 Элан Фармасьютикелз, Инк. КОНЪЮГАТЫ Aβ ИММУНОГЕННЫХ ПЕПТИДНЫХ НОСИТЕЛЕЙ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
AU2005294131A1 (en) 2004-10-05 2006-04-20 Wyeth Methods and compositions for improving recombinant protein production
US20060160161A1 (en) 2004-10-26 2006-07-20 Elan Pharmaceuticals, Inc. Methods for assessing antibodies to neurodegenerative disease-associated antigens
WO2006066118A2 (en) 2004-12-15 2006-06-22 Neuralab Limited Contextual fear test for predicting efficacy of alzheimer immunotherapeutic treatment
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
EP1838349A1 (en) 2004-12-15 2007-10-03 Neuralab, Ltd. Amyloid beta antibodies for use in improving cognition
US20060240486A1 (en) 2004-12-15 2006-10-26 Johnson-Wood Kelly L Immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies
WO2006066049A2 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
MX2007009091A (es) 2005-01-28 2008-01-11 Wyeth Corp Formulaciones de polipeptido liquidas estabilizadas.
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US7825223B2 (en) 2005-06-17 2010-11-02 Janssen Alzheimer Immunotherapy Methods of purifying anti A β antibodies

Also Published As

Publication number Publication date
EP1636268B8 (en) 2012-03-21
CN1798766A (zh) 2006-07-05
EA200501891A1 (ru) 2006-06-30
EP1636268A4 (en) 2007-02-21
AU2004245989B2 (en) 2011-06-16
PT1636268E (pt) 2012-05-23
IL171877A (en) 2012-05-31
KR101455479B1 (ko) 2014-10-28
CA2525975A1 (en) 2004-12-16
ECSP056263A (es) 2006-04-19
JP4908203B2 (ja) 2012-04-04
HK1088617A1 (en) 2006-11-10
PL1636268T3 (pl) 2012-07-31
BRPI0410860A (pt) 2006-07-04
CN1798766B (zh) 2012-05-30
US20050118651A1 (en) 2005-06-02
CO5660296A2 (es) 2006-07-31
NZ544324A (en) 2009-05-31
TWI306458B (en) 2009-02-21
IL171877A0 (en) 2006-04-10
DK1636268T3 (da) 2012-05-29
NO20055415L (no) 2006-02-20
ZA200509585B (en) 2009-01-28
PE20050627A1 (es) 2005-08-10
UA90846C2 (ru) 2010-06-10
EP1636268B1 (en) 2012-02-15
KR101152583B1 (ko) 2012-07-17
MY176959A (en) 2020-08-27
AR044580A1 (es) 2005-09-21
KR20120060949A (ko) 2012-06-12
MXPA05012718A (es) 2006-02-08
TW200510458A (en) 2005-03-16
SI1636268T1 (sl) 2012-06-29
EP1636268A2 (en) 2006-03-22
NO20055415D0 (no) 2005-11-16
UY28337A1 (es) 2004-12-31
KR20060024389A (ko) 2006-03-16
JP2007536895A (ja) 2007-12-20
TW200911830A (en) 2009-03-16
ATE545656T1 (de) 2012-03-15
AU2004245989A1 (en) 2004-12-16
WO2004108895A2 (en) 2004-12-16
CA2525975C (en) 2014-09-23
EA012407B1 (ru) 2009-10-30
US7871615B2 (en) 2011-01-18
WO2004108895A3 (en) 2005-07-28
TWI374893B (en) 2012-10-21
ES2382547T3 (es) 2012-06-11

Similar Documents

Publication Publication Date Title
CR8095A (es) Anticuerpos humanizados que reconocen el cuerpo beta amiloideo
UY29284A1 (es) Anticuerpos ab(beta) humanizados usados en mejorar la cognicion
UY29282A1 (es) Anticuerpos humanizados que reconocen el peptido beta amiloideo
CY1110963T1 (el) Εξανθρωπισμενα αντισωματα που αναγνωριζουν πεπτιδιο βητα αμυλοειδους
ECSP034685A (es) Anticuerpos humanizados que reconocen el peptido amiloideo beta
UY29283A1 (es) Anticuerpos ab(beta)usados en mejorar la cognicion
UY29504A1 (es) Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
DE60239931D1 (de) Kombinationstherapie
EA200700427A1 (ru) Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
EA200401170A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
DOP2006000013A (es) Dosis de anticuerpos en el tratamiento de enfermedades asociadas a las celulas b
CY1113094T1 (el) Ανοσοσφαιρινες κατευθυνομενες εναντι nogo
CR9512A (es) Metodos para el tratamiento de tumores de cerebro con anticuerpos
CR8230A (es) Sondas para enfermedades en las cuales se acumula amiloide, agentes para tincion del amiloide, farmacos para tratamiento y profilaxis de enfermedades con amiloide acumulado y sondas para diagnostico de ovillos neuro fibrilares yagentes...
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
BRPI0414513A (pt) kid3 e anticorpos de kid3 que se ligam a ele
CY1113310T1 (el) Εξανθρωπισμενα αντισωματα ειδικα για nogo-a και φαρμακευτικες χρησεις αυτων
MX2020009532A (es) Oligonucleotidos modificados para uso en el tratamiento de tauopatias.
GT200400231A (es) Compuestos de sulfoniltetrahidro-3h-benzo(e)indol-8-amina como ligandos de la 5-hidroxitriptamina-6.
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
TW200740845A (en) Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue
WO2009120659A3 (en) Human monoclonal antibodies against amyloid beta protein, and their use as therapeutic agents
ECSP003492A (es) Prevencion y tratamiento de enfermedades amiloidogenicas
WO2009120657A3 (en) Human monoclonal antibodies against amyloid beta protein, and their use as therapeutic agents